BiBBInstruments Expands EUS-LB Capabilities
BiBBInstruments advances liver biopsy techniques with EndoDrill® GI, showcasing promising results in recent clinical trials.
Sammanfattning
BiBBInstruments' recent trials at UKM demonstrate the potential of EndoDrill® GI for liver biopsies, marking a significant advancement in endoscopic procedures.
BiBBInstruments, a prominent player in the field of cancer diagnostics, has made significant strides in the realm of endoscopic ultrasound-guided liver biopsy (EUS-LB) with its innovative EndoDrill® GI instrument. This recent development was highlighted during a collaborative session at the University Hospital Münster (UKM), where the EndoDrill® GI was employed in two clinical cases to investigate non-malignant liver diseases.
Under the expert guidance of Professor Barbara Braden and Dr. Michael Praktiknjo, the trials successfully obtained core tissue biopsies, which are akin to surgical biopsies in their ability to provide intact tissue samples with preserved architecture. These samples are now under evaluation for diagnostic outcomes, potentially setting a new standard in minimally invasive biopsy techniques.
Dr. Charles Walther, the founder and CMO of BiBBInstruments, expressed his enthusiasm about the potential of this method, stating, 'Liver is a challenging and relatively new area for endoscopic sampling. We need to learn more, but it was inspiring to see tissue sampling with true core biopsies.'
The EndoDrill® GI is the world’s first market-approved powered biopsy instrument for endoscopic ultrasound (EUS), having received FDA 510(k) clearance in the USA in 2023 and CE approval in Europe in early 2024. This approval marks a significant milestone for BiBBInstruments as it positions the company at the forefront of innovations in diagnostic procedures for gastrointestinal organs.
For investors, the advancements in EUS-LB present an intriguing opportunity. With the commencement of the commercialization phase in early 2025 and the first order from a US university hospital, BiBBInstruments is poised for growth. The company's strategic focus on enhancing diagnostic precision for severe cancers aligns well with the increasing demand for minimally invasive diagnostic tools.
Considering these developments, stakeholders might consider holding their positions in BiBBInstruments. The company’s innovative approach and recent approvals indicate a strong potential for future growth, making it an attractive option for long-term investment.
Källa
Sammanfattning
Dr. Charles Walther, grundare och CMO för BiBB, kommenterar att lever är ett nytt och utmanande område för endoskopisk provtagning, men att det är inspirerande att se vävnadsprovtagning med kärnbiopsier. Endoskopiskt ultraljudsstyrd leverbiopsi (EUS-LB) är en ny metod för levervävnadsprovtagning, som erbjuder ett minimalt invasivt alternativ till traditionella tekniker för diagnos av leversjukdomar. BiBB besökte universitetssjukhuset Münster för att stödja leverprovtagning med EndoDrill® GI i två kliniska fall, där kärnvävnadsbiopsier togs för att utreda icke-maligna leversjukdomar. EndoDrill® GI är världens första eldrivna biopsiinstrument för endoskopiskt ultraljud, godkänt i USA och Europa, och används för vävnadsprovtagning i mag-tarmkanalen. BiBB, grundat av Dr. Charles Walther, utvecklar EndoDrill®-instrumenten för att förbättra diagnostiken av allvarliga cancersjukdomar. Bolaget är baserat i Lund och noterat på Spotlight Stock Market.
